7 unknown. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vosoritide for Short Stature in Turner Syndrome Vosoritide - Turner Syndrome, Short Stature | Phase 2 | Unknown | Roopa Kanakatti Shankar, MBBS, MS | 20 | 2024-04-12 | 2024-06-24 |
| Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome Bumetanide, Placebo - Down Syndrome | Phase 2 | Unknown | Stefano Vicari | 64 | 2023-01-11 | 2024-06-20 |
| Metformin in Patients With Fragile X Metformin, Placebo oral tablet - Fragile X Syndrome | Phase 1 / Phase 2 | Unknown | Rowan University | 40 | 2019-10-29 | 2019-10-31 |
| A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) Diazoxide choline controlled-release tablet - Prader-Willi Syndrome | Phase 2 | Unknown | Essentialis, Inc. | 32 | 2017-07-01 | 2016-09-09 |
| A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome PEG-rhGH low dose, PEG-rhGH high dose, Non-treatment control group - Turner Syndrome | Phase 2 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 180 | 2016-03-01 | 2017-12-12 |
| Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. omega-3 PUFAs, Standard care, placebo - 22q11 Deletion Syndrome | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 80 | 2014-06-01 | 2014-02-25 |
| Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21 Fluor varnish, Fluor varnish with nanoparticles - Down Syndrome | Phase 2 | Unknown | Universidad Autonoma de San Luis Potosí | 20 | 2012-09-01 | 2014-03-07 |
Down Syndrome (2) · Turner Syndrome (2) · 22q11 Deletion Syndrome (1) · Dwarfism (1) · Fragile X Syndrome (1) · Prader-Willi Syndrome (1) · Psychotic Disorders (1)
Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Abnormalities, Multiple (4) · Intellectual Disability (4) · Nervous System Diseases (4) · Neurobehavioral Manifestations (4) · Neurologic Manifestations (4) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3) · Endocrine System Diseases (3) · Heart Defects, Congenital (3) · Heart Diseases (3) · Sex Chromosome Disorders (3)
Bumetanide (1) · Fish Oils (1) · Metformin (1) · Nanoparticles (1) · Standard of Care (1) · colloidal silver (1) · polyethylene glycol-recombinant human growth hormone (1) · vosoritide (1)
Bambino Gesù Hospital and Research Institute (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Essentialis, Inc. (1) · Roopa Kanakatti Shankar, MBBS, MS (1) · Rowan University (1) · Stefano Vicari (1) · Universidad Autonoma de San Luis Potosí (1)
United States (2) · China (1) · Holy See (1) · Italy (1) · Mexico (1)
Chunxiu Gong, PhD (1) · Marco Armando, MD, PhD (1) · Roopa Kanakatti Shankar, MBBS, MS (1) · Sean McBride, MD, PhD (1) · Stefano Vicari (1)